Formulation and Evaluation of Fixed-Dose Combination of Bilayer Gastroretentive Matrix Tablet Containing Atorvastatin as Fast-Release and Atenolol as Sustained-Release

<table>IR spectra of atorvastatin-<i>β</i>-CD solid systems in 1 : 2 (drug/CD) molar ratio: (a) atorvastatin powder; (b) pure <i>β</i>-CD; (c) physical mixture of atorvastatin with <i>β</i>-CD; (d) solvent evaporation product of atorvastatin with <i>β</i>-CD.</table>

BioMed Research International

fig4

Figure 4

Figure 4: Formulation and Evaluation of Fixed-Dose Combination of Bilayer Gastroretentive Matrix Tablet Containing Atorvastatin as Fast-Release and Atenolol as Sustained-Release 

Figure 4 | Formulation and Evaluation of Fixed-Dose Combination of Bilayer Gastroretentive Matrix Tablet Containing Atorvastatin as Fast-Release and Atenolol as Sustained-Release 